SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
January 24, 2022 06:00 ET
|
SAB Biotherapeutics, Inc.
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700...
SAB Biotherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
January 05, 2022 07:00 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
SAB Biotherapeutics Added to NASDAQ Biotechnology Index
December 20, 2021 06:00 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...
SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
December 16, 2021 06:00 ET
|
SAB Biotherapeutics, Inc.
FDA laboratory testing confirms SAB-185 neutralizes Omicronand other variants of concern with in vitro pseudovirus model SAB’s targeted, highly potent and fully-human polyclonal antibodies continue...
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
December 01, 2021 07:00 ET
|
SAB Biotherapeutics, Inc.
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by...
SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update
November 22, 2021 07:00 ET
|
Sab Biotherapeutics, Inc.
Advanced SAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at interim analysis Awarded additional $60.5 million from DoD in expanded...
SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
October 25, 2021 07:40 ET
|
Sab Biotherapeutics, Inc.
Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” SIOUX FALLS, S.D.,...